Phase 2 Start~month
Phase 2 Start: MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination With Eithe
- Company
- GH Research PLC (GHRS)
- Drug
- mosunetuzumab
- Indication
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Splenic Marginal Zone Lymphoma
Other upcoming events for GHRS
Phase 2 StartPhase 2 Start: A Phase 1/2 Open-Label Intrathecal Administration of TSHA-105 to Determine the Safety and Efficacy i
Phase 2 StartPhase 2 Start: Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled
Phase 2 StartPhase 2 Start: A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Transl
Phase 1 StartPhase 1 Start: A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects Wi
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.